STAGE IV PROSTATE CANCER AJCC V8

This early-phase trial tested the safety of combining two drugs, nivolumab and cabozantinib, in 8 people with HIV who also have advanced solid tumors. The goal was to see if the combination is safe and can shrink or stabilize the cancer. The study focused on finding the right dos…

This study tests whether combining two drugs, golimumab and apalutamide, can help men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The goal is to see if this combination can lower PSA levels by at least 50%. Eight participants are e…

This early-phase trial tests a new treatment for men with advanced prostate cancer that no longer responds to hormone therapy. The treatment uses the patient's own immune cells, modified in a lab to recognize and attack cancer cells. The main goals are to find the safest dose and…

This early-stage trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in adults with advanced prostate, bladder, or kidney cancer that has spread. The goal is to find the safest dose and see if the combination can help control the disease. About 65 particip…

This study tests whether adding an experimental drug (M6620) to standard chemotherapy can better shrink tumors or slow the disease in men with advanced prostate cancer that no longer responds to hormone therapy. About 73 participants will receive either M6620 plus carboplatin or …

This study is for men whose prostate cancer has returned or spread to a few spots after initial treatment. It compares two types of radiation therapy given over a shorter time to see if they are safer and still effective. The goal is to control the disease with fewer side effects…

This study tests a two-step treatment for men with an aggressive form of prostate cancer that has spread. First, patients receive chemotherapy plus an immunotherapy drug. Then, they take a maintenance drug (niraparib) either alone or with more immunotherapy. The goal is to see if…

This study tests the safety and effectiveness of combining the immunotherapy drug avelumab with other treatments (utomilumab, anti-OX40 antibody, and radiation) in 173 adults with advanced solid tumors that have spread. The goal is to find the best doses and see if these combinat…

This study tests whether combining two drugs, vidutolimod and nivolumab, can help the immune system attack and destroy prostate cancer cells that have spread to other parts of the body. The trial is for men with metastatic castration-resistant prostate cancer who have already tri…

This early-phase trial is testing whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate that have spread. About 15 participants will receive the combinatio…

This study looks at whether men whose metastatic prostate cancer has responded very well to hormone therapy can safely pause treatment. About 79 men will stop their medications under doctor guidance to see if their testosterone levels recover and they remain cancer-free for at le…

This study tests a combination of three drugs (abiraterone, prednisone, and apalutamide) in 60 men whose prostate cancer has spread but who have not yet received hormone therapy. The goal is to see how long patients can stay on treatment and to measure cancer progression and side…

This study tests whether adding rucaparib to standard enzalutamide treatment helps men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About 61 participants will receive either the combination or enzalutamide alone. The goal is to see if t…